| Literature DB >> 30895120 |
Qizhang Wang1, Jiyuan Liu1, Shuqun Qi1, Xuejuan Liao1, Dazhong Liu2, Jian Pan1.
Abstract
BACKGROUND/Entities:
Keywords: Bisphosphate; Osteonecrosis; Risk factor; Treatment
Year: 2018 PMID: 30895120 PMCID: PMC6388813 DOI: 10.1016/j.jds.2017.12.003
Source DB: PubMed Journal: J Dent Sci ISSN: 1991-7902 Impact factor: 2.080
Figure 1The fraction of each osteonecrosis.
Figure 2Number of MRONJ and non-MRONJ from 2006 to 2017.
BPa type and systemic disease of MRONJb patients.
| prostate cancer | 7 (23.3%) |
| osteoporosis | 7 (23.3%) |
| breast cancer | 5 (16.7) |
| multiple myeloma | 3 (10%) |
| lung cancer | 1 (3.3%) |
| cervical cancer | 1 (3.3%) |
| leukemia | 1 (3.3%) |
| Zoledronate | 12 (50%) |
| Pamidronate | 1 (4.2%) |
| Alendronate | 4 (16.7%) |
BP: bisphosphonate.
MRONJ: medication related osteonecrosis of the jaws.
Demographic analysis of the collected data.
| Group | Patient number | Age (mean ± SD) | Gender ratio | Location ratio |
|---|---|---|---|---|
| MRONJ | 30 (14.93%) | 64.43 ± 14.041 | 16:14 (1.14) | 11.19 (0.58) |
| ORN | 33 (16.42%) | 55.61 ± 11.630 | 24:9 (2.67) | 4:30 (0.13) |
| Odontogenic osteonecrosis | 94 (46.77%) | 46.64 ± 17.218 | 54:40 (1.35) | 10:85 (0.12) |
| Trauma & surgical induced osteonecrosis | 14 (6.97%) | 33.00 ± 22.405 | 9:5 (1.8) | 0:14 |
| Cause-Unknown | 30 (14.93%) | 45.33 ± 23.072 | 12:18 (0.67) | 5:27 (0.19) |
MRONJ: medication related osteonecrosis of the jaws.
ORN: Osteoradionecrosis.
In surgery and trauma groups, none of patients' lesion occurred in the maxilla.
ORN, Odontogenic osteonecrosis, Cause-Unknown groups had 1, 1, 2 lesions occurred in both the jaws respectively.
General and local risk factor of ONJs.a
| Risk factor | No. of MRONJ | No. of ORN | No. of OO | No. of TSO | No. of CU |
|---|---|---|---|---|---|
| hypertension | 5 (16.7%) | 4 (12.1) | 9 (9.6%) | 0 | 5 (16.7%) |
| diabetes mellitus | 6 (20%)* | 2 (6.1%) | 3 (3.2%)* | 0 | 0 |
| Corticosteroid and immunosuppressant | 4 (13.3%) | 1 (3.0%) | 6 (6.4%) | 0 | 3 (10%) |
| smoke | 11 (36.7%) | 12 (36.4%) | 36 (38.3%) | 5 (35.7%) | 8 (26.7%) |
| alcohol | 9 (30%) | 12 (36.4%) | 34 (36.2%) | 4 (18.6%) | 8 (26.7%) |
| Tooth extraction | 24 (80%)* | 9 (27.3%)* | 65 (69.1%) | 2 (14.3%)* | 0* |
| Multi-extraction | 14 (58.3%)* | 2 (22.1%) | 13 (20%)* | 2 (100%) | 0 |
| Secondary extraction | 3 (12.5%) | 0 | 6 (9.2%) | 0 | 0 |
| Periodontal disease | 5 (16.7%) | 5 (15.2%) | 3 (3.2%) | 1 (7.1%) | 2 (6.7%) |
| Poor oral hygiene | 8 (26.7%) | 8 (24.2%) | 12 (12.8%) | 4 (18.6%) | 7 (23.3%) |
| Inappropriate prosthesis | 3 (10%) | 1 (3.0%) | 9 (9.6%) | 2 (14.3%) | 2 (6.7%) |
Data with asterisks means there are statistically difference between MRONJ and these groups.
ONJ: osteonecrosis of the jaw.
MRONJ: medication related osteonecrosis of the jaws.
ORN: Osteoradionecrosis.
OO: Odontogenic osteonecrosis.
TSO: Trauma and surgical induced osteonecrosis.
CU: Cause-Unknown.
Multi-extraction: more than one tooth extracted one time.
Secondary extraction: teeth extracted for more than one time.
Staging of medication-related osteonecrosis of the jaw.
| Staging | Symptoms and signs |
|---|---|
| Stage 0 | patients without specific exposed necrotic bone, but with non-specific symptoms or clinical and imaging findings, such as pain, radiographic non-healing bone in extraction sockets. |
| Stage 1 | Patients with exposed and necrotic bone or fistulas but no evidence of infection. |
| Stage 2 | Patients with exposed and necrotic bone or fistulas as well as clinical infection symptoms. |
| Stage 3 | Based on stage II, patients with severe clinical presentations, such as pathologic fracture, extra-oral fistula, osteolysis extending to the maxillary sinus floor or inferior border of the mandible. |
Figure 3Clinical image of mandibular uncovered, necrotic bone in a MRONJ patient.
Figure 4Clinical image of pus and skin fistula and pus in an MRONJ patient.
Figure 5A female patient who had BPs usage history for breast cancer, six months after tooth extraction: Clinical image of the oral fistula (black arrow) and uncovered extraction socket (white arrow).
Clinical presentations of MRONJa patients.
| Clinical presentations of MRONJ | No. of MRONJ |
|---|---|
| Exposed bone | 27 (90%) |
| Pain or discomfort | 24 (80%) |
| Swelling | 18 (60%) |
| Pus | 17 (56.7%) |
| Trismus | 8 (26.7%) |
| Paresthesia | 5 (16.7%) |
| Oral fistula | 7 (23.3%) |
| Skin fistula | 4 (13.3%) |
| Halitosis | 2 (6.7%) |
| Hemorrhage | 2 (6.7%) |
MRONJ: medication related osteonecrosis of the jaws.
Figure 6Dental panoramic radiography showing a sequestra in the right mandible region (black arrow).
Figure 7Cone beam CT showing osteosclerosis around the loose tooth (black arrow).
Imaging features of MRONJa patients.
| Imaging features of MRONJ | No. of MRONJ |
|---|---|
| Sequestra | 16 (53.3%) |
| Osteolysis | 17 (56.7%) |
| Osteosclerosis | 12 (40%) |
| Non-healing extraction socket | 8 (26.7%) |
| Periosteal reaction | 7 (23.3%) |
| Irregularity of the cortical margins | 4 (13.3%) |
| Maxillary sinusitis | 8 (26.7%) |
| Involvement of mandibular canal | 2 (6.7%) |
| Pathologic fracture | 1 (3.3%) |
MRONJ: medication related osteonecrosis of the jaws.
Treatment outcomes of MRONJa patients.
| Treatment | No. of MRONJ | No. of improvement | No. of no improvement |
|---|---|---|---|
| Surgical treatment | 16 | 13 (81.3%) | 3 (18.7%) |
| Conservative treatment | 11 | 5 (45.5%) | 6 (54.5%) |
MRONJ: medication related osteonecrosis of the jaws.